Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

660 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-03

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natural History Study of CADASIL

NCT05072483

Cardiovascular Disease Arterial Stiffness Germline Mutation in the NOTCH 3 Gene +2 more

RECRUITING

Registry for CADASIL

NCT05567744

Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy

RECRUITING

AusCADASIL: An Australian Cohort of CADASIL

NCT06148051

Cadasil

RECRUITING

Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease

NCT05306834

Cerebral Small Vessel Diseases Stroke Dementia

RECRUITING NA

Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study

NCT06453252

Stroke, Ischemic Intracranial Atherosclerosis Posterior Circulation Brain Infarction

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is the most common monogenic vascular dementia. Individuals with CADASIL are destined to develop vascular cognitive impairment and dementia (VCID), which can be studied in pre-symptomatic and prodromal disease stages to detect the earliest changes in biological fluids, neuroimaging, and the emerging phenotype of symptomatic VCID.

The objective of the proposed research is to exploit an autosomal dominant vascular dementia as a model to investigate specific features of VCID and to examine interactions with risk factors impacting the aging life course.

The study will enroll a total of 575 participants with a CADASIL family history who have had a genetic test for a NOTCH3 variant. Participants will complete: a clinical interview, a neurological exam, neurocognitive and behavior assessments, MRI, and a blood draw at each study visit. Participants will complete 3 in-person visits in total as part of this study: baseline, visit 2 (18 months after baseline), visit 3 (36 months after baseline). Additional contact will occur by phone, mail, email or the internet as needed and will be referred to as "remote visits".

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CADASIL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non-Carrier Cohort

About 100 participants who are at-risk, healthy family members with No NOTCH3 Mutation and no symptoms or signs of cognitive decline.